GenoMed Chief Medical Officer to Present Data at Two Conferences in September
ST. LOUIS, Sept. 11 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Bulletin Board: GMED)- ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that its Chairman and Chief Medical Officer, David Moskowitz MD, will be presenting the company's data at two conferences next week.
On Wednesday, September 18, Dr. Moskowitz will present a poster on the first day of the World Genomics Symposium & Exposition being held in Atlantic City (http://www.world-genomics.com). His poster will be entitled "Improved Patient Outcomes Thanks to Medical Genomics: Diabetic and Hypertensive Renal Failure in White and Black Men." The poster will describe kidney patients' outcomes using GenoMed's patent-pending treatment, which was published yesterday.
On Friday of next week (September 20), Dr. Moskowitz will address the 7th Annual Disease Management Congress meeting at the Sheraton Hotel & Towers, Chicago, IL (http://www.nmhcc.org/dmc). His topic will be "Next Generation Disease Management(TM): From Pharmacogenomics to Improved Patient Outcomes." His talk will describe a new pro-active form of Disease Management, guided by knowledge of disease genes, which only GenoMed currently offers.
Dr. Moskowitz stated, "GenoMed has treatment programs which could potentially benefit hundreds of millions of patients world-wide. It is incumbent on the company to get the word out. Presentation of our data at genomic and clinical conferences is one of the most effective ways to inform colleagues and decision-makers of what we have to offer. I am excited to do my part."
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) reported that the company has applied for patents based on its finding that the ACE gene is associated with over 40 common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use. A video version of the company's treatment results for chronic kidney failure is available at 216.234.225.2
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer of GenoMed, +1-877-GENOMED, fax, 314-977-0042,
or kfischer@genomedics.com
Web site: genomedics.com
world-genomics.com
216.234.225.2
nmhcc.org
. |
